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Superficial femoral artery thrombosis as a cause for
distal embolism in primary antiphospholipid
syndrome
Lannery S. Lauvao, MD, Kaoru R. Goshima, MD, Luis R. Leon Jr, MD, RVT, Paul E. Nolan, PharmD,
and John D. Hughes, MD, Tucson, Ariz
Antiphospholipid syndrome is a diagnosis with the clinical manifestations of thromboses in the presence of an antiphospho-
lipid antibody. A 25-year-old man with a history of deep venous thrombosis, pulmonary emboli, and myocardial infarction,
and receiving long-term anticoagulation with warfarin, all due to primary antiphospholipid syndrome, presented with blue
toe syndrome from a primary superficial femoral artery thrombus. He was anticoagulated with fondaparinux in addition
to dipyridamole and aspirin perioperatively. The area of thrombus was resected and reconstructed using a cephalic vein
interposition graft. This report reviews antiphospholipid syndrome and identifies potential questions and problems
relating to a rare clinical presentation. (J Vasc Surg 2008;48:472-7.)The association between antiphospholipid syndrome
(APS) and hypercoagulability has been well described. Its
definite diagnosis is made by the presence of (1) at least one
type of antiphospholipid antibody and (2) the clinical
manifestations of venous and arterial thromboses, recurrent
fetal loss, or thrombocytopenia.1 Although venous throm-
boses predominate, lower extremity arterial thromboses or
thromboembolism, or both, are distinctly uncommon. In
this report, we present a patient diagnosed with primary
APS who had blue toe syndrome from a superficial femoral
artery thrombotic source.
CASE REPORT
A 25-year-old man, who did not smoke, presented to our
vascular clinic with a 6-week history of painful left toe ulcers. His
history included APS and heparin-induced thrombocytopenia
(HIT), both diagnosed at another institution 8 years earlier after
he had sustained a pulmonary embolism from bilateral lower
extremity deep vein thrombosis (DVT). An inferior vena cava filter
(IVCF) placement was deemed necessary at that time. There was
no mention of failed anticoagulation therapy.
Since then, postphlebitic syndrome with bilateral venous stasis
ulcers had developed. He was also diagnosed with a myocardial
infarction 1-year prior at another institution after complaining of
chest pains and with elevated troponin levels. He was managed
conservatively, with maintenance of anticoagulation with warfarin
and aspirin. Records documented that his cardiac event was likely
related to hypercoagulability.
Review of his history showed that a definite diagnosis of APS
was due to his documented thrombotic events and the presence of
anticardiolipin immunoglobulin G (IgG) antibodies of 149 U
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472glycopeptidolipid (reference range, 80 interpreted “high posi-
tive”). This was his second positive test result for anticardiolipin
IgG antibody in several years. The results of the rest of his hyper-
coagulable workup, including factor V Leiden and prothrombin
gene mutations, were normal. Levels of antithrombin III, protein
C, and protein S levels were essentially not interpretable because all
were drawn during an acute thrombotic event. Owing to his high
risk of thrombosis if he were to stop taking warfarin, these levels
were not repeated. His current medications included warfarin,
aspirin, hydrochlorothiazide, and simvastatin.
The physical examination noted bilateral lower extremity
edema and anterior tibial ulcers relating to venous stasis (Fig 1,
Left). The first and fifth toes on his left foot had distal ulcerations,
and the third and fourth toes showed tender, flat, punctate bluish
discolored lesions (Fig 1, Right). His pulse examination result was
normal.
Recent laboratory values showed normal results for complete
blood cell count and chemistry profile. Coagulation studies
showed an elevated prothrombin time, with an international nor-
malized ratio (INR) of 2.5 and a partial thromboplastin time that
was twice the control level.
A cardiac echocardiogram showed distal hypokinesis of the left
ventricle consistent with a previous myocardial infarction. There
were no findings to suggest a cardiac thrombus. Computed to-
mography (CT) angiography of the chest, abdomen, and pelvis was
unremarkable for arterial lesions but confirmed the presence of an
IVCF and caval thrombosis distal to the filter. Left leg arterial
duplex ultrasound imaging revealed velocities 400 cm/s at the
midsuperficial femoral artery (SFA) level. These findings were used
to establish a diagnosis of left blue toe syndrome from a likely SFA
lesion, and surgical intervention was recommended.
Five days before surgery, warfarin was stopped and fondapa-
rinux injections, dipyridamole, and aspirin were started. Heparin-
associated antibody detection by enzyme-linked immunosorbent
assay was re-sent and results were negative.
Intraoperatively, a left lower extremity angiogram demon-
strated a 3-cm filling defect in the left mid-SFA (Fig 2). Surgical
exposure of this area, after a single dose of heparin (5000 U),
revealed gross periarterial inflammation and fibrosis. Its lumen
al di
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Left). Resection and reconstruction using an end-to-end left ce-
phalic vein interposition graft was then performed (Fig 3, Right).
Histopathologic evaluation had shown an organized thrombus
with recanalization and without evidence of atherosclerosis or
Fig 1. Left, An active venous stasis ulcer is shown affect
shown affecting the left first and fifth toes. The left thir
lesions, likely precursors of ulcers, in the context of norm
Fig 2. Angiography of the left lower extremity shows a smooth
filling defect affecting the middle third of the superficial femoral
artery, thought to be the culprit of the distal embolic phenome-
non. The normal appearance of the rest of the artery and the lack of
collateral vessels are noteworthy, confirming the lack of atheroscle-
rosis as an etiologic factor for this patient’s complaints.vasculitis in the affected vessel wall (Fig 4).Warfarin was restarted on the first postoperative day while
maintaining fondaparinux, aspirin, and dipyridamole. The pa-
tient’s platelet count remained normal throughout his hospital
course. Before he was discharged on postoperative day 4, a
repeat left thigh arterial duplex ultrasound scan revealed veloc-
ities of 158 cm/s, reflecting a patent graft. He was seen at 2
weeks, 1 month, and 3 months, in routine postoperative clinic
evaluation with a patent graft and healed toe ulcers. Warfarin,
dipyridamole, and aspirin therapy will be continued indefinitely.
The patient was enrolled in a periodic graft surveillance pro-
gram.
DISCUSSION
The diagnosis of APS is based on the presence of
antiphospholipid antibodies and the clinical manifestations
of arterial or venous thrombosis, recurrent fetal loss, or
thrombocytopenia.1 The major antiphospholipid antibod-
ies associated with APS include lupus anticoagulants, anti-
cardiolipin antibodies, and antibodies to 2 glycoprotein-
I.1-7 In a large series of 1000 APS patients, 15.2% had both
venous and arterial thrombosis, with most the arterial ves-
sels being cerebral.8 In the Euro-Phospholipid Project,
4.3% of patients with APS cumulatively presented with
arterial lower extremity thrombosis.8 This study, however,
did not differentiate atherosclerosis from thromboembolic
events in APS patients. Therefore, the true incidence of
primary arterial thrombosis affecting peripheral extremities
e pretibial area of our patient.Right, Punctate ulcers are
forth toes had tender, flat, punctate bluish discolored
stal pulses.ing th
d andin APS is unknown.
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thrombosis includes the initiation of unfractionated or
low-molecular-weight (LMW) heparin, with a transition
to oral warfarin therapy.1,9 Strong clinical evidence sup-
ports this approach for the treatment of APS-associated
venous thrombosis, yet there is weakness of data on
primary or recurrent arterial events.10 In contrast with
cerebral ischemia in APS patients,11 no specific clinical
trials have been designed to evaluate the optimal therapy
of noncerebral arterial thrombosis.1,10 Furthermore,
Fig 3. Left, Intraoperative photograph shows the lum
demonstrating organized thrombus and periarterial fib
evident upon surgical manipulation. Right, The pho
interposition graft.
Fig 4. Histopathologic section of arterial vessel wall shows
thrombus without evidence for atherosclerosis. Hemotoxylin and
eosin staining, 40 original magnification.there is uncertainty with the optimal treatment for recur-rent thromboembolic events, as in the case of our pa-
tient. This has been reported as high as 7% despite
warfarin therapy.9 Thrombocytopenia has been associ-
ated with APS. It is important clinically to differentiate
patients with HIT and thrombocytopenia associated
with APS. HIT patients with APS are a separate chal-
lenge that requires modifications in therapy. This can
include other antithrombotic regimens such as synthetic
hirudins, argatroban, and fondaparinux, which normally
do not cross-react with HIT antibodies.12-14
Our patient presented a challenge of all three pro-
portions. He presented acutely with an isolated periph-
eral arterial thrombotic lesion of unclear etiology, his
thrombotic episode occurred while he was receiving
warfarin therapy and aspirin, and he carried a diagnosis of
HIT, which we needed to confirm. Once an embolic
source was ruled unlikely, we can only hypothesize that
the femoral lesion was a result of a local or a transient
systemic inflammatory process related to his disease
that led to endothelial dysfunction, complement and
platelet activation, and ultimately, thrombus forma-
tion.15-18 This lesion subsequently caused distal arterial
embolism culminating as blue toe syndrome and toe
ulcerations. Thrombosis due to premature or accelerated
atherosclerosis in setting of traditional risk factors
(smoking, diabetes, hypertension, and hypercholesterol-
emia) have been documented in APS patients.19-21 De-
of the left superficial femoral artery at its distal third
No periarterial calcification or intimal thickening was
ph shows the final appearance of the cephalic veinen
rosis.
tograspite this view of vasculopathy in APS, our patient’s
ion;C
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atherosclerosis to support this concept.
A recent randomized control trial, Antiphospholipid
Antibody Acetylsalicylic Acid (APLASA),22 showed that
asymptomatic patients with antiphospholipid antibodies
generally are not recommended aspirin to prevent throm-
bosis. In contrast, antiphospholipid antibody–positive pa-
tients with documented thromboses are recommended he-
parinization and managed long term with oral warfarin
therapy to a targeted INR between 2 and 3.23,24 The
addition of an antiplatelet agent such as aspirin decreases
platelet activity and may benefit APS patients with cardiac
manifestations.25
Operating on a patient with known primary APS
without perioperative anticoagulation has been associ-
ated with a very high risk for graft thrombosis.26 There-
fore, a strict perioperative anticoagulation regimen is
paramount. We re-sent a heparin-associated antibody
detection panel and proceeded with our surgical inter-
vention by initiating fondaparinux in combination with
aspirin and dipyridamole for additional antiplatelet activ-
ity. With a negative documentation for HIT, we are
hopeful that this drastically opens this patient’s options
for potential future anticoagulation strategies. This can
include adding LMW heparin to therapeutic warfarin if a
rethrombosis were to occur.10 To further aid in reducing
the risk of graft failure, an autogenous conduit was our
choice. The cephalic vein was selected because of the
diseased leg veins from chronic venous hypertension and
reflux as a result of caval and lower extremity venous
Table. Lower extremity arterial manifestations in primary
First
author
(year)
Age/
sex Symptoms
Site on
angiography
Shortell
(1992)28
48/F Toe gangrene Not mentioned
65/
M
Toe gangrene Fem-pop
41/F LE gangrene Fem-pop
52/F Blue toes Aortoiliac
27/
M
Severe claudication Bilateral popliteal
Nitecki
(1993)26
19/F Claudication, ulcer Not mentioned
38/F Claudication, ulcer Not mentioned
38/
M
Claudication/gangrene Not mentioned
Jicha
(1994)29
12/F Toe necrosis CFA, SFA, ATA
ABF,Aortobifemoral;ATA, anterior tibial artery; BKA, below knee amputat
SFA, superficial femoral artery.thrombosis.The role for surgical intervention in primary APS of the
lower extremity arteries is unclear. Asherson et al27 re-
ported a collective experience of seven patients with pri-
mary APS involving the lower extremities where the out-
comes were amputations. However, this report did not
mention if perioperative anticoagulation was ever used or if
previous limb salvage procedures were undertaken. The
Table reports selected primary APS patients with lower
extremity arterial thromboembolic manifestations.28,29
These interventions were associated with early failure rates
thought to be largely due to the absence of perioperative
anticoagulation. This observation was documented by Ahn
et al,30 who noticed the rate of thrombosis correlated
highly with lack of perioperative anticoagulants or anti-
platelet agents in vascular procedures in patients with lupus
anticoagulants.
Other studies of lower extremity bypass operations
have been reported in patients with antiphospholipid
antibodies. Lee et al31 reported no differences in graft
patency, limb salvage, and patient survival rates for pa-
tients with or without antiphospholipid antibodies un-
dergoing elective infrainguinal bypass grafting. Lam et
al32 showed that patients with antiphospholipid antibod-
ies who underwent lower extremity bypass operations
will likely have progression of atherosclerosis. However,
these articles did not report whether these patients with
positive antibodies had primary or secondary antiphos-
pholipid syndrome.21 We cannot find any scientific evi-
dence in the form of clinical trials for optimal medical or
surgical therapy, or both, for APS patients who present
hospholipid syndrome
Treatment
Post-op
Anticoagulation
with warfarin Outcome
mbar sympathectomy None Temporary
improvement
-pop bypass graft None Occluded 2 mon
-pop graft revision None Occluded 12 mon
oral endarterectomy None Occluded 6 mon,
BKA
femoral bypass None Occluded 5 mon
rtobifemoral bypass None Thrombosed 24 h
F thrombectomy None Patent at 1 mon
ateral fem-pop bypass Not mentioned Thrombosed
vision fem-pop Patent at 6 mon
nservative-pentoxifylline None Ulcer improved
nservative-pentoxifylline None Ulcer healed
-pop bypass None Thrombosed 2 d
nservative-heparin Warfarin No evidence
recurrent
Thrombotic events;
duration not
mentioned
FA, common femoral artery; Fem-pop, femoropopliteal; LE, lower extremity;antip
Lu
Fem
Fem
Fem
Ilio
Ao
AB
Bil
Re
Co
Co
Fem
Cowith nonatherosclerotic thromboembolic events in
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is unavoidable, perioperative and long-term anticoagu-
lation is essential.
We recognize that sometimes it is difficult to differ-
entiate an embolus from primary thrombosis, especially
in absence of classic findings of atherosclerotic disease
and cardiac arrhythmia. Our conclusion for APS throm-
bosis was supported by our in situ evaluation of the
grossly abnormal vessel and the pathologist’s final de-
scription and conclusion. The femoral thrombus was
adherent to the vessel wall and recanalization had oc-
curred to suggest it was chronic. Our negative cardiac
source workup and angiographic imaging further sug-
gests primary thrombosis. The occluded IVCF also
makes it unlikely for a lower extremity DVT paradoxic
embolic event to have occurred. To our knowledge, our
report represents a rare case of distal embolization
caused by isolated SFA thrombosis in a patient diagnosed
with primary APS.
CONCLUSIONS
Antiphospholipid syndrome is a coagulation disorder
that often leads to thrombosis. Primary peripheral arte-
rial thrombosis is rare in APS. Patients can present with
severe acute limb ischemia or in a subtler manner with
microemboli and blue toe syndrome. With an aggressive
anticoagulation regimen, arterial reconstruction seems
to be safe and feasible. Studies are needed to establish
optimal anticoagulation regimens for recurrent throm-
boses while patients are receiving warfarin therapy. Fur-
thermore, studies are needed to define optimal medical
and surgical therapy for primary thrombosis of peripheral
arterial vessels associated with APS.
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